Thermo Fisher stock falls as CEO flags new U.S. reshoring contracts, Nvidia tie-up in focus
Thermo Fisher Scientific’s pharma services unit secured contracts to help clients move drug manufacturing back to the U.S., CEO Marc Casper said Tuesday. Shares fell 1.4% to $607.08. The company announced new AI partnerships with Nvidia and TetraScience and confirmed COO Michel Lagarde will leave by March, with Gianluca Pettiti named as his successor. Casper cited looming tariffs and recent acquisitions as drivers for U.S. expansion.